Aptocrom

앱토크롬 · 109960

Industrials Trading & Distribution · KOSDAQ

Small-cap

Market cap US$17.4M (₩24.1B)

Overview

Aptocrom distributes prescription and over-the-counter medicines, including topical treatments, digestive drugs, nutritional supplements, and antibiotics, to the healthcare market in South Korea.

It also leases its own real estate and equipment, and through a subsidiary provides specialist thermal-insulation systems for nuclear power plants. Listed on KOSDAQ, South Korea's tech and small-cap exchange, the company operates across three distinct segments: pharmaceuticals distribution, property rental, and insulation services.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$7.1M

▼ −40.2% YoY

Operating profit · FY2025

−US$1.7M

Turned to loss

Net income · FY2025

−US$4.1M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$11.6M(₩16B)	US$11.9M(₩16.4B)	US$7.1M(₩9.8B)
Operating profit	US$136.7K(₩188.6M)	US$700.4K(₩966.6M)	−US$1.7M(−₩2.3B)
Net income	US$3M(₩4.2B)	−US$20.3M(−₩28B)	−US$4.1M(−₩5.6B)

Revenue

FY2023US$11.6M
FY2024US$11.9M
FY2025US$7.1M

Operating profit

FY2023US$136.7K
FY2024US$700.4K
FY2025−US$1.7M

Net income

FY2023US$3M
FY2024−US$20.3M
FY2025−US$4.1M

Key ratios (FY2025)

ROE

-1.8%

Debt/Eq

4.5%

Op. margin

-23.3%

Net margin

-57.5%

Rev. YoY

▼ −40.2%

Why it matters

Aptocrom's subsidiary 에이프로젠아이앤씨㈜ focuses on nuclear-plant-specific insulation design, fabrication, and installation, a highly regulated niche within South Korea's energy infrastructure sector.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?